For instance, A2M-AS1 has been reported to have regulatory effects on downstream factors such as CD2 and SELL, in the cell adhesion molecule pathway, indicating that A2M-AS1 may be a visible candidate prognostic factor and therapeutic target for breast cancer [36]. This evidence concerns the gene SELL and breast cancer.